Neuroimaging has made it possible to measure pathological brain changes associated with
Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been …

In the past 10 years, there has been a virtual explosion in the literature concerning the
construct of mild cognitive impairment. The interest in this topic demonstrates the increasing …

The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since
the publication of the new MCI definition at the K ey S ymposium in 2003, but the core …

We performed this research to 1) evaluate a novel deep learning method for the diagnosis of
Alzheimer's disease (AD) and 2) jointly predict the Mini Mental State Examination (MMSE) …

The NINCDS–ADRDA and the DSM-IV-TR criteria for Alzheimer's disease (AD) are the
prevailing diagnostic standards in research; however, they have now fallen behind the …

In this review, we report on studies that have assessed the effects of exogenous and
endogenous increases in stress hormones on human cognitive performance. We first …

One of the major neuropathological findings in the brains of individuals with Alzheimer's
disease (AD) is a loss of synaptic contacts in both the neocortex and hippocampus. Here we …

To date, most diagnostic imaging comparisons between amyloid labelling ligands and other
imaging modalities have been between the use of amyloid labelling ligand 11C Pittsburgh …

The demographics of aging suggest a great need for the early diagnosis of dementia and
the development of preventive strategies. Neuropathology and structural MRI studies have …

Biomarkers of brain Aβ amyloid deposition can be measured either by cerebrospinal fluid
Aβ42 or Pittsburgh compound B positron emission tomography imaging. Our objective was …